Capricor Therapeutics Faces Securities Fraud Lawsuit; Deadline Approaching
Capricor Therapeutics has been sued for securities fraud over alleged misstatements about Deramiocel and its clinical data integrity, leading to a 64% stock drop. Investors must file claims by September 28.
Capricor Therapeutics is facing a securities fraud class action lawsuit, with investors who suffered losses required to submit their claims by September 28. The lawsuit alleges misstatements concerning the company's drug candidate, Deramiocel, and the integrity of the clinical data supporting its Biologics License Application (BLA).
The company's stock price experienced a significant decline of 64% following these allegations. The class action suit was initiated by investors who claim to have incurred financial losses due to the company's purported misrepresentations. This legal action represents a critical development for Capricor Therapeutics.
The case underscores the importance of transparency in the pharmaceutical industry and the role of regulatory oversight. Investors are expected to seek compensation for documented losses resulting from potentially misleading information provided by the company.
Further legal proceedings are anticipated, and the outcome could have implications for Capricor Therapeutics and investor protection within the broader biotechnology sector.